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Abstract  
Background: Early phase trials are essential in drug development, determining 
appropriate dose levels and assessing preliminary activity. These trials are 
undertaken by industry and academia, with increasing collaborations between the 
two. There is pressure to perform these trials quickly, safely and robustly. However, 
there are inherent differences between developing and managing early phase, 
compared to late phase, drug trials. This paper describes an approach to 
establishing an academically-led early phase trial portfolio, highlighting lessons 
learned and sharing experiences.  
Methods: In 2009 the University of Leeds Clinical Trials Research Unit became the 
Clinical TULDOV&RRUGLQDWLQJ2IILFHIRU0\HORPD8.¶VSKDVH,DQG,,WULDOV:H
embarked on a transition from working extensively in phase III to early phase trials 
development and conduct. This involved evaluating and revising our well-established 
standard operating procedures, visiting other academic early phase units, and 
developing essential new documentation and processes.  
Results: A core team of trial and data managers and statisticians was established to 
facilitate expertise and knowledge retention. A detailed training plan was 
implemented focusing on essential standard practices for early phase. These 
included pharmacovigilance, recruitment, trial design and set-up, data and site 
monitoring, and oversight committees. Training in statistical methods for early phase 
trials was incorporated. 
Conclusion: Initial scoping of early phase trial management and conduct was 
essential in establishing this early phase portfolio. Many of the processes developed 
were successful. However, regular review and evaluation were implemented to 
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enable changes and ensure efficiencies. It is recommended that others embarking 
on this venture build on the experiences described in this article.  
 
Keywords: Early phase; phase I; phase II; cancer trials; 
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Introduction 
Translation of early (predominantly basic) research to the clinic is a well-recognised 
challenge in the drug development pathway.1 Challenges arise in academia with 
limited relevant funding streams, complexities in designing early phase studies, and 
the necessary iterative collaboration between laboratory scientists, clinical 
researchers and industry partners. Early phase drug trials, including phase I and II, 
are essential steps in the development pathway, delivering research from bench to 
bedside, and providing proof of concept to move to large scale phase III testing and 
beyond. There is, however, an inevitable high attrition at these earlier stages, due to 
emerging safety concerns, changing industry priorities, or withdrawal of drugs from 
company development pipelines, all adding layers of complexity. 
 
With continuing pressure to develop new drugs and novel treatment combinations 
that offer improved patient outcomes, it is essential that early phase trials are 
conducted quickly, safely and efficiently. Historically, the majority of early clinical 
trials have focussed on new drugs and drug combinations using tried and tested trial 
designs, predominantly undertaken by industry and developed in line with their 
strategic priorities. There are now more opportunities to develop academically-led 
early phase trials in the UK in previously under-explored areas, particularly in the 
field of oncology where early phase trials involve patients and are often conducted 
differently to other disease areas. Successful initiatives in oncology such as the 
Experimental Cancer Medicine Centre (ECMC) Combinations Alliance provide a 
framework to develop such studies using novel drugs made available from a number 
of industry partners.2 There are also opportunities to evaluate drug repurposing from 
one therapeutic area to another, allowing knowledge transfer. For successful 
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delivery, it is essential that investigators are supported by academic clinical trials 
units (CTUs) with expertise in developing and managing early phase trials within the 
regulatory framework. While there are currently 49 UK Clinical Research 
Collaboration registered CTUs in the UK,3 there are notable differences between 
developing and managing small, often safety-driven, early phase trials, as compared 
to large-scale multi-centre phase III trials. However, the current registration system 
assesses only expertise and experience associated with the latter. CTU expertise in 
early phase trials is scarce, with only 13/49 registered CTUs having expertise in 
phase I trial design and delivery.4 Across Europe, approximately one third of 
European Clinical Research Infrastructure Network centres conduct phase I trials, 
compared to 85% conducting phase III.5 
 
The University of Leeds Clinical Trials Research Unit (CTRU) is a UK Clinical 
Research Collaboration registered unit and one of 15 members of the National 
Cancer Research Institute Cancer Clinical Trials Units Group. The CTRU has an 
international record in late phase trials across cancer and other disease areas, 
undertaking associated methodological research. In 2009 Myeloma UK set out an 
innovative research model to rapidly and systematically address the challenges that 
slow down research and the development and access to new drugs for myeloma 
patients. Part of this model was to establish a clinical trials network to deliver 
prioritised phase I and II trials. Leeds CTRU was successfully awarded a grant to 
become the Clinical Trials Coordinating Office for the Myeloma UK Clinical Trials 
Network, providing infrastructure funding to lead the design, central coordination, 
GDWDPDQDJHPHQWDQGDQDO\VLVRIWKH1HWZRUN¶VWULDOSRUWIROLR6LQFHWKHQDSRUWIROLR
of 6 phase I and 7 phase II protocols have been developed through the Network,6-8 
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funded through industry partnerships and Myeloma UK, and the CTRU has 
expanded its early phase research into other disease areas, including the initiation of 
the Yorkshire Cancer Research Centre for Early Phase Clinical Trials. 
 
The aim of this paper is to describe the approach to establishing an academically-led 
early phase drug trial portfolio at the CTRU, highlighting the key processes 
developed, lessons learned, and providing recommendations to enable others to 
develop similar trials infrastructure to share in our experience. 
 
 
Initial scoping 
Building on existing links with national and international academic trials units already 
running phase I and II trials, the senior management team, consisting of clinical, 
statistical, trial management, data management and operational staff, visited two 
academic units DQG&DQFHU5HVHDUFK8.¶VWKHQ'UXJ'HYHORSPHQW2IILFHto learn 
from their experiences. This was essential in gaining an understanding of key 
processes for managing early phase trials and how they differ to later phase studies. 
This information was used to develop a framework of standard operating procedures 
and guidelines for phase I and II trials, and an associated training program for staff. 
In addition, key guidance on best practice in early phase trials was reviewed and 
incorporated.9 The studies undertaken by CTRU were carefully selected on the basis 
RIDIXOOLQWHUQDOULVNDVVHVVPHQWDQGGLVFXVVLRQZLWKWKHWULDOV¶6SRQVRU8QLYHUVLW\
of Leeds). It is important to note, however, that the phase I trials undertaken at 
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CTRU were not first in human studies. Guidance and best practice relating to these 
studies was, however, adopted where appropriate.10  
 
Key considerations and recommendations 
Establishing a core team  
Table 1 summarises the key recommendations for establishing a core team. The 
CTRU initiated a strategy to transfer existing late phase trial skills to the early phase 
setting. The first action was to establish a dedicated core team of researchers 
including clinicians, trialists and statisticians, working towards facilitating knowledge 
development, retention and specialisation.  The CTRU team was headed by the co-
Director of the cancer division with significant experience in myeloma trials, a lead 
statistician with phase II methodological expertise, and a lead trial manager.  An 
independent advisory committee was established comprising clinicians with phase I 
and II trials expertise. It was necessary to appoint staff with a high level of 
experience and expertise to conduct the projects. 
Due to the early nature of these trials alternative approaches were required 
compared to the phase III setting, with a higher degree of monitoring, increased site 
visits, intensive source data verification, closer and more intensive data management 
and statistical input and tracking of safety and risk profile. At the time of initiating the 
early phase portfolio, electronic data capture (EDC) was not used within CTRU., with 
data return via paper-based case report forms (CRFs). The key difference compared 
with high-risk phase III trials was therefore the short time frames in which CRF 
return, data entry and validation needs to occur.  
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CTRU staff managing late phase clinical trials specialised in either trial or data 
management. Due to the small scale nature of phase I trials it was more efficient to 
amalgamate roles, with a trial manager taking on data management responsibilities 
including data validation and data querying.  Database development and 
maintenance was provided by the CTRU IS department. The combined role ensured 
knowledge of the trial and trial patients was strengthened in a smaller, core team 
including a senior trial manager operating across a number of early phase trials, 
ensuring day to day oversight of the portfolio and providing appropriate cover where 
necessary, and a data management assistant providing data entry and querying 
support. The combined role, requiring the core competencies of both trial and data 
management, ensured the person responsible had in depth knowledge of the whole 
trial protocol including treatment schedules, safety monitoring requirements, and 
follow-up schedules. This enabled efficient monitoring of recruitment, data return and 
safety data closely and effectively. Safety data was then reviewed more widely by 
the chief investigator and safety review committee.   
 
Phase II trials are typically larger than for phase I, impacting the number of sites 
recruiting and amount of data collected. Acknowledging the higher risk relative to 
phase III it was found that the phase III model of both a trial manager and a data 
manager, working together to ensure effective delivery, worked adequately for these 
trials.  
  
A team of two statisticians was established initially to focus solely on phase I and II 
trials and the associated statistical methodology. This enabled expertise to be 
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developed in a number of early phase designs. These include phase I algorithm-
based designs such as the 3+3 approach, which provide a pre-specified set of rules 
to determine dose escalation according to the number of dose limiting toxicity (DLT) 
events observed within an individual dose cohort, and model-based designs such as 
the continuous reassessment method which apply a statistical model to the DLT 
events observed across all cohorts in order to make dose escalation 
recommendations based on a pre-specified target toxicity rate.11-13 For phase II this 
includes multi-outcome designs,14 which enable decisions regarding trial continuation 
to be made on a number of intermediate outcomes. Typically, the investment of 
statistical time for these trials is in design evaluation. Core infrastructure support 
from MUK enabled statisticians to commit time to identification, development and 
evaluation of appropriate statistical designs up-front. This was essential to ensure 
that the most appropriate and reliable designs were used.   
  
Table 1 Recommendations for establishing a core trial team 
x Identify core trial and data managers and statisticians to work wholly on phase 
I and II trials, to ensure coherent and well trained team.  
x Combine trial and data management roles in phase I trials. 
x Allow statisticians to develop methodological knowledge and provide 
dedicated time to design trials.  
 
Establishing standard practices 
Table 2 summarises key recommendations for establishing standard practices. 
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Pharmacovigilance 
As is standard across all drug trials, there is a requirement to report any safety 
concerns to the relevant competent authority in Europe and the FDA in the USA. 
Pharmacovigilance processes were already well established within CTRU for later 
phase trials and required little adaptation for the handling of Serious Adverse Events 
and Suspected Unexpected Serious Adverse Reactions in the phase I and II setting. 
The speed for reporting safety events to CTRU was considered acceptable for the 
higher risk of the trials (within 24 hours of event occurring) as was the time to 
process these in-house and react to any issues. For later phase trials run through 
the CTRU, the Principal Investigator at site assigns causality and expectedness of a 
Serious Adverse Event. This may not be overruled by the Chief Investigator unless 
the Principal Investigator felt appropriate. However, for early phase trials, 
participating sites typically have limited experience of the drug. The Chief 
Investigator is therefore permitted to overrule local assignment and re-assess based 
on their experience with the drug, following discussion with the Principal Investigator. 
This approach is different to that in the USA where the trial Sponsor assesses 
causality and where adverse reactions are a subset of all suspected adverse 
reactions.  
The main difference for phase I trials was the requirement for sites to report dose 
limiting toxicities (DLTs). The need for rapid reporting (within 24 hours of occurrence) 
and urgency of processing a DLT was incorporated as a pharmacovigilance task in 
line with existing processes for Serious Adverse Events and Suspected Unexpected 
Serious Adverse Reactions. This approach also ensured rapid Chief Investigator 
review to allow any necessary action to be expedited.  
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Trial Design and Set Up 
Although early phase trials may be smaller than phase III trials, the time required to 
develop their design and set them up is typically no different, and in some instances 
can be longer. It is essential that the most appropriate designs are considered for 
both phase I and II. Typically, for phase I trials, patients are recruited in cohorts of 2-
3 patients at a time to the same dose level, with dose escalation only permitted once 
safety evaluation of the current dose level has been undertaken and escalation 
deemed safe. Consideration should be given to alternative methods to the 3+3 
design for dose escalation to ensure robust and reliable results are generated to 
inform future research.15, 16 The 3+3 design uses a pre-specified standard set of 
rules to determine dose escalation/de-escalation according to the number of DLT 
events observed at each individual dose level, escalating if 0/3 events are observed, 
increasing the cohort size if 1/3 DLTs are observed, and de-escalating or declaring a 
GRVHWRRWR[LFLI'/7V observed. While this may be the default approach for 
many studies, an investment of time to develop expertise in alternative methodology 
is a crucial element of establishing an early phase trials unit. Within CTRU the first 2 
phase I trials developed used the 3+3 design to enable us to learn about real-life 
practicalities of running these trials. However, later trials have adopted model-based 
approaches, as described earlier, as we have built our knowledge in this area. Thus, 
the design stage requires intensive input from the statistician, often involving 
extensive simulations, ongoing discussions with the clinical team and write up of 
design documentation. This time is, however, often countered by the somewhat 
decreased time required for analysis, as compared with large scale phase III trials. 
Furthermore, it is essential that decision-making criteria for dose-escalation in phase 
I and interim and final analyses in phase II are fully specified at the start of the trial. 
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These should be fully transparent in the protocol and the statistical analysis plan, 
which, as for phase III trials, should ideally be drafted prior to opening to recruitment. 
A lengthy development and set-up period impacts the overall timelines, and the 
resources needed to complete these trials. Although many phase I and II trials 
require a relatively small number of participants, this is not always reflected in their 
cost and duration.  
 
Patient recruitment 
Due to the nature of phase I trials, a restrictive recruitment procedure was 
implemented to limit the number of patients treated at each dose level as per the 
underlying dose escalation design, and recruitment was monitored closely. For the 
initial Myeloma UK phase I trials, only three patients at a time were recruited to each 
cohort, with a gap between the 1st and 2nd patient at the first dose level to reflect best 
practice. Only three or four centres were open to recruitment at any time to allow 
easy tracking of potential patients. Centres were selected on the basis of having a 
track record in recruiting into and delivering high quality drug trials in myeloma, and 
good standards in collecting and reporting data. It was also critical that sites had 
early phase trials experience, with many centres being Experimental Cancer 
Medicine Centres (centres with world-leading expertise in early phase research).17 
Regular and active communication with centres was essential in order to track 
patients closely. Processes for monitoring treatment compliance for patients on trial 
treatment were also developed to ensure patients received sufficient treatment to be 
evaluated for safety and to highlight any dosing errors. Knowing where patients were 
in the trial pathway was essential, as was keeping sites informed, to aid recruiting in 
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a timely manner. Being able to respond quickly to replace patients who withdrew 
from trial for any reason prevented hold-ups in recruitment and facilitated steady 
recruitment. Accounting for patient attrition due to non-eligibility or non-evaluability 
was also essential to ensure the correct number of patients are recruited, treated 
and have data available for analysis. A two-stage process to log patients approached 
about the trial and given a patient information sheet, and those subsequently 
consenting and assessed for eligibility was implemented, helping to prevent over 
recruitment. This enabled valuable assessment of patterns of recruitment and, in the 
case of slower than anticipated recruitment, an in-depth evaluation of potential 
barriers.  
 
Central and site data monitoring 
It became clear from discussions with other early phase units that more intensive 
monitoring of trial data was required than for some of the late phase trials due to 
their higher safety risk. CTRU¶V phase III process for risk assessment and monitoring 
plans were adapted for the early phase setting. Fast data turnaround from sites was 
stipulated for critical data items, ensuring safety review of laboratory parameters and 
eligibility criteria. Return of data within 48 hours of key clinic visits was mandated 
initially.  
 
Data review was expedited, with data entry within 24 hours of receipt of paper CRFs 
and all data entry validation and querying  within 48 hours. Drug dosing and safety 
data were actioned immediately if required. Data monitoring focused on early 
treatment cycles to monitor closely events that may meet DLT criteria or could 
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possibly become a DLT. Regular communication with sites regarding these events 
was essential in delivering safe, robust and timely trials. Safety and endpoint data 
were monitored stringently in an ongoing basis, via both automated data validation 
and manual review. Data queries were sent to sites with a tight turnaround time to 
allow data cleaning; this was especially pertinent for data required for dose 
escalation decision meetings. Sites were chased for outstanding data on a weekly 
basis and were requested to return CRFs within 24 hours of completion. Priority 
queries were raised immediately and requested to be returned within 48 hours.  
 
These strict turnaround times led inevitably to frequent intensive data chases. Many 
sites were unable to achieve this strict turnaround requirement and, although the 
importance of returning data within these timelines was re-iterated, the original 
timelines set were not viable. The timelines were reviewed to ensure essential data 
were appropriately returned within 24 hours, and other data within 48 hours to 1 
week, CRF dependent. However, data compliance and quality issues still continue 
due to high staff turnover at sites; an issue beyond the control of a trials unit. In an 
attempt to improve data return there is now a move to use EDC specifically within 
the early phase division at CTRU. This is currently being implemented for the next 
Myeloma UK trial.   
 
Source data verification was conducted on a more frequent basis than in our phase 
III trials. A risk assessment was undertaken during trial set-up to determine key 
areas of risk within the trial and an appropriate monitoring plan created. For phase I 
trials this typically involved a monitoring visit within 2 weeks of each patient being 
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enrolled and a further visit at the end of the first treatment cycle to ensure 100% of 
data relating to patient safety and dose escalation review was verified. At phase II a 
typical monitoring plan involved a minimum of 3 visits per site, the first visit taking 
place within 6±8 weeks of first patient enrolled, with 100% of their data monitored at 
this time point. Second and third visits would be scheduled in line with key risk points 
such as second randomisations or transition to maintenance treatment for patients 
already enrolled in the study, and typically 100% of data relating to the primary 
endpoint would be monitored for a random sample of approximately 2-3 further 
patients at each site, to highlight any issues with data recording.  
The intensive monitoring required for early phase drug trials inevitably impacts on 
resource and cost, with more staff required to ensure monitoring is completed fully in 
the timeframes required.  
 
Independent oversight committees 
Within phase I trials the requirement for more frequent, detailed independent review 
of safety data is a key process that differs to phase III. Reflecting on the experiences 
of other units it was agreed that a Dose Escalation Review Group including 
independent clinical members, physicians recruiting to the trial, the Chief Investigator 
and key CTRU staff (statistician and trial manager), would be convened to meet 
regularly throughout the trial to assess safety data and determine dosing decisions 
(escalation, de-escalation, or remaining at the same dose level). The choice of Dose 
Escalation Review Group members was made to ensure expertise with the specific 
treatment under evaluation, and to ensure input from recruiting clinicians to enable 
detailed discussion about individual patients. Independent members with expertise 
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both in phase I and the disease and/or treatment under evaluation ensured an 
unbiased opinion in decision-making. All members were made aware of the need to 
contribute and be available for these discussions. 
 
A report comprising individual patient safety and treatment data for patients treated 
at each dose level was generated via a database report and presented to the Dose 
Escalation Review Group. Specific emphasis was placed on DLTs, Serious Adverse 
Events, Suspected Unexpected Serious Adverse Reactions, all adverse events and 
any dose modifications made. It was important that the decision to dose escalate or 
not was made in a quick and timely manner to allow the trial to continue to recruit 
without significant delays whilst maintaining rigor. Meetings were planned as soon as 
the last patient was recruited to each dose level, or with pre-emptive monthly 
meetings in the diary to be cancelled should the meeting not be needed at that time. 
Perhaps inevitably, the latter approach has proved more successful since scheduling 
ad hoc meetings with only few ZHHNV¶QRWLFHDQGDQXPEHURIDWWHQGHHVZDV
problematic.  
 
For phase II trials, more traditional oversight committees were established (Data 
Monitoring and Ethics Committee (DMEC) and Trial Steering Committee (TSC)). For 
the Myeloma UK trials, umbrella committees were established to review all phase II 
trials within the Network, facilitating knowledge retention and consistency. To further 
facilitate this, standard DMEC and TSC template reports were developed, 
incorporating detailed safety reporting. Choice of DMEC and TSC members was 
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driven by expertise in the disease area, and early phase clinical and statistical 
expertise.  
 
Table 2 Recommendations for establishing standard practice 
x Awareness of time commitment and statistical input required in designing and 
setting up phase I and II trials is essential, for the trials unit, funders and 
Networks.  
x Decision-making criteria for dose escalation in phase I and for interim and 
final analysis in phase II must be fully specified in the protocol and statistical 
analysis plan, prior to opening to recruitment. 
x Include only 3-4 centres in recruitment during dose escalation in a phase I 
trial, to enable close monitoring of patients  
x Implement regular communication with sites to ensure they meet their set-up 
timeframes required by National Institute for Health Research, to ensure 
tracking of patients recruited to phase I trials, and to ensure timely data return. 
x Ensure sites are fully trained and aware of timeframes for data capture and 
return 
x Select oversight committee members on the basis of their experience in the 
disease area of interest, as well as specific phase I and/or phase II clinical or 
statistical expertise. Should a clinician have only disease-specific expertise, 
additional clinical members should be sought to ensure phase I and/or phase 
II expertise is incorporated within the committee. 
x While phase II trial oversight committees do not differ from those of larger 
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phase III drug trials, the key differences are within the phase I setting where a 
dose escalation review group who meet regularly and incorporate 
independent clinicians is essential to the expedited review of safety and dose 
escalation decision making. 
x Ensure the Chief Investigator and independent reviewer are fully aware of 
timeframes required for reviewing pharmacovigilance reports. 
x Ensure regular dose escalation review group meetings are pre-arranged and 
regular safety reports provided to the DMEC. 
 
 
Establishing a training plan 
Key recommendations for establishing a training plan are summarised in Table 3. 
Training a dedicated team of early phase specialists was intensive, requiring them to 
fully understand the processes being implemented and the urgency of the 
information dealt with on a daily basis. An in-house training plan was developed 
covering each of the processes associated with early phase trials including extended 
pharmacovigilance to ensure correct reporting of dose limiting toxicities and an in 
depth understanding of intensive data review. External training was sought where 
required (e.g. disease- and treatment-specific and statistical methodology training 
including courses at Lancaster University, Society for Clinical Trials conference 18, 
and the first Early Phase Dose Finding Symposium). Regular staff development and 
re-training was implemented to ensure continuing professional development and a 
high level of attention to detail. In particular, training was developed to provide staff 
with a thorough understanding of the different roles of Dose Escalation Review 
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Group, DMEC and TSC groups, highlighting where these differ to the phase III drug 
setting and the importance of timely review by each of these. Although early phase 
specialists can move from trial to trial with more ease than those with experience of 
late phase moving to early phase, a detailed in-house training plan was still required 
to ensure staff were familiar with a QHZWULDO¶Vdesign and requirements. The benefits 
of having a highly trained team ensured trials ran efficiently and without serious 
error, and enabled staff to develop a specific area of expertise.  
As previously discussed, we developed statistical expertise in the design of phase I 
and II trials. Methodological training courses external to CTRU were identified to 
support this, as well as providing dedicated time to develop an understanding of the 
methodology and to implement this in practice. 
 
Table 3 Recommendations for establishing a training plan 
x An in-house training plan should be developed to provide staff with a thorough 
understanding of early phase trials and the specific elements that differ to 
undertaking late phase drug trials.  
x Key training includes pharmacovigilance reporting, independent review 
committees for phase I, and statistical methodology. 
x Regular review of training plans and re-training is required. 
 
 
Discussion 
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Within the first six years of establishing the Myeloma UK Clinical Trials Network and 
Coordinating Office, a total of 13 trials have been developed,6-8 two of which did not 
open due to safety concerns during development and withdrawal of industry support.  
During this time we have learnt that, due to the early phase nature of these studies 
and working closely with industry, there is a significant time investment in developing 
a study whilst negotiations are ongoing. This inevitably leads to amendments to 
study design and logistics, requiring a degree of flexibility in study development.  
 
A dedicated team of CTRU staff has proven essential in maintaining high standards 
of trial, data and statistical management required for these trials and ensuring 
knowledge retention. While some of the processes may be similar to those for phase 
III drug trials, having a dedicated team for the duration of a trial allows an expertise 
to be built in early phase processes. Learning from day-to-day contact with sites and 
repetition of trial-specific queries has allowed relationships to be built with sites, 
facilitating promotion of trials and resolution of issues. This has also proven effective 
when setting up new trials. Staff retention has been aided by the training and 
development programme which encourages staff to progress and develop their skills 
and expertise within early phase drug trials. Most recently this has enabled 
implementation of novel statistical methodology for new trials in development,13, 14, 19 
supported by focused training, increased engagement with the clinical team, and 
dedicated time to learn, understand and implement new methods.  
 
The high throughput of trials within the early phase portfolio has led to continued 
review of processes and review of areas where efficiencies may be made. For 
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example, publication policies used for late phase trials were implemented for early 
phase restricting publication to the end of the trial when the primary end point would 
have been available and preventing the publication of pertinent data such as 
laboratory data or dose escalation data not linked to the primary efficacy end point. 
This has been problematic for some of our early phase trials where presentation of 
early data on safety, activity and translational research has been important to 
communicate to the wider clinical community. An early phase publication policy is 
currently being drafted to allow flexibility to report findings in a timely manner. We 
would recommend all early phase trials have an associated publication plan which is 
reviewed and agreed with the trial oversight committees, to ensure transparency in 
reporting of data throughout the trial and at final analysis.  
 
In many areas it has been possible to standardise processes and documents. This 
has been particularly apparent within the MUK Network due to similarities between 
trials with regard to disease background, trial endpoints and reporting processes. 
Standardising documents has helped reduce the need for multiple document reviews 
and enabled familiarity with processes and paperwork both at CTRU and at 
recruiting sites, which are often the same for many trials. Standardisation of 
processes and documentation specific to Myeloma UK trials includes patient 
registration, protocol writing, patient information sheets and informed consent, case 
report forms & database specifications, data reports (e.g. DMEC and TSC reports) 
and contracts. Many of these processes have been developed to be more widely 
applicable to all phase I and II trials within CTRU, with key components relating to 
phase I compared to phase II acknowledged. 
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The experiences described focus on academic early phase oncology trials, which 
can be considered somewhat different to early phase trials in other disease areas. 
The nature of trial design, in particular phase I, outside of cancer will also differ 
according to the specific indication, and patient populations may be less restrictive, 
with initial dose finding studies being conducted in healthy volunteers rather than 
patients. Standardisation of processes and documentation across disease areas will 
differ according to different requirements of other disease areas. However many of 
the concepts described are transferable. In depth knowledge of disease area, trial 
protocol and individual patients in the study is essential for any early phase trial, as 
is a tailored training program for staff. The recommendations provided may be seen 
as an initial starting point for those undertaking academic early phase trial design 
and management in other disease areas.  
 
Learning from experiences of each trial and reflecting on elements that work well and 
areas that are more challenging ensures continued improvement with each new trial. 
Initial scoping of early phase trial management and conduct was an essential 
process in establishing the &758¶Vearly phase portfolio, however much more has 
been learned from setting up and conducting each of the trials and learning from our 
experiences. For academic trials units embarking on early phase clinical trials it 
would be strongly recommend to build on the experiences described to assist in 
portfolio set-up. 
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